aldo-keto reductase family 1 member C6, pseudogeneGenealiases: []
Q-omics provides the consensus-scored AKR1C6P profile across patient tissues and cancer cell-line models. AKR1C6P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, AKR1C6P is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, AKR1C6P RNA expression shows 11,179 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, and LSCC as cancer lineages where AKR1C6P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AKR1C6P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AKR1C6P survival associations across molecular data types. AKR1C6P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AKR1C6P RNA expression–survival associations across cancer types. High AKR1C6P expression shows unfavorable associations in KIRP, THCA, ACC and THYM, but favorable associations in HNSC and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for AKR1C6P RNA expression.
This table summarizes AKR1C6P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for AKR1C6P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AKR1C6P shows lower tumor expression in THCA and CHOL and higher tumor expression in HNSC, COAD, LUSC and ESCA. The HNSC box plot shows higher AKR1C6P RNA expression in tumor versus normal tissue (log2 FC = +0.172, t-test p = .002).
This table shows molecular features associated with AKR1C6P in patient tissues and cancer cell lines. In patient samples, AKR1C6P shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, AKR1C6P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY.
